Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8356 to 8370 of 8901 results

  1. Induction of labour in late intrauterine fetal death: vaginal misoprostol (after oral mifepristone) (ESUOM11)

    This evidence summary has been updated and replaced by NICE guideline NG207.

    Withdrawn advice

  2. Chronic obstructive pulmonary disease: glycopyrronium bromide (ESNM9)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Withdrawn advice

  3. Hypersalivation: oral glycopyrronium bromide (ESUOM15)

    This evidence summary has been withdrawn because licensed products are now available and the off-label indication has been replaced by NICE guideline NG71.

    Withdrawn advice

  4. Nocturia and nocturnal polyuria in men with lower urinary tract symptoms: oral desmopressin (ESUOM10)

    This evidence summary has been withdrawn because a product containing oral desmopressin with a marketing authorisation for treating nocturia and nocturnal polyuria in men with lower urinary tract symptom is now available in the UK.

    Withdrawn advice

  5. Generalised anxiety disorder: quetiapine (ESUOM12)

    This evidence summary has been updated and replaced by NICE guideline CG113 and subsequent surveillance reviews.

    Withdrawn advice

  6. Preventing recurrence of Clostridium difficile infection: bezlotoxumab (ES13)

    This advice has been updated and replaced by NICE guideline NG199.

    Withdrawn advice

  7. Non-cystic fibrosis bronchiectasis: inhaled tobramycin (ES12)

    This evidence summary has been updated and replaced by NICE guideline NG117.

    Withdrawn advice

  8. Early breast cancer (preventing recurrence and improving survival): adjuvant bisphosphonates (ES15)

    This evidence summary has been updated and replaced by NICE guideline NG101.

    Withdrawn advice

  9. Obese, overweight with risk factors: liraglutide (Saxenda) (ES14)

    This evidence summary has been updated and replaced by NICE technology appraisal guidance 664.

    Withdrawn advice

  10. Chronic obstructive pulmonary disease: fluticasone furoate, umeclidinium and vilanterol (Trelegy) (ES18)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Withdrawn advice

  11. Doxylamine/pyridoxine (Xonvea) for treating nausea and vomiting of pregnancy (ES20)

    This evidence summary has been updated and replaced by NICE guideline NG201.

    Withdrawn advice

  12. Antimicrobial prescribing: Ceftazidime/avibactam (ES16)

    This evidence summary has been updated and replaced by NICE antimicrobial health technology evaluation guidance on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections.  

    Withdrawn advice

  13. Chronic obstructive pulmonary disease: beclometasone, formoterol and glycopyrronium (Trimbow) (ES17)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Withdrawn advice

  14. Oestrogen deficiency symptoms in postmenopausal women: conjugated oestrogens and bazedoxifene acetate (ES3)

    This evidence summary has been withdrawn because the product is no longer available in the UK.

    Withdrawn advice

  15. Antimicrobial prescribing: nebulised liposomal amikacin (ES36)

    This evidence summary has been withdrawn. An NHS England clinical commissioning policy on nebulised liposomal amikacin for the treatment of non-tuberculous mycobacterial pulmonary disease caused by mycobacterium avium complex is available.

    Withdrawn advice